These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 20932171)

  • 61. Trypanocidal nitroarene treatment of experimental Trypanosoma cruzi infection does not prevent progression of chronic-phase heart lesions in rabbits.
    Teixeira AR; Cunha Neto E; Rizzo LV; Silva R
    J Infect Dis; 1990 Dec; 162(6):1420. PubMed ID: 2121842
    [No Abstract]   [Full Text] [Related]  

  • 62. [Chagas disease and immunodeficiency: HIV infection and transplantation].
    Le Loup G; Ibrahim K; Malvy D
    Bull Soc Pathol Exot; 2009 Dec; 102(5):310-8. PubMed ID: 20131425
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The need of a neonatal preparation for Chagas disease.
    Sosa-Estani S; Belizan JM; Althabe F; Rubinstein A
    PLoS Med; 2005 Nov; 2(11):e387. PubMed ID: 16288560
    [No Abstract]   [Full Text] [Related]  

  • 64. Safety Profile of Nifurtimox and Treatment Interruption for Chronic Chagas Disease in Colombian Adults.
    Olivera MJ; Cucunubá ZM; Álvarez CA; Nicholls RS
    Am J Trop Med Hyg; 2015 Dec; 93(6):1224-1230. PubMed ID: 26392162
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Usefulness of PCR for monitoring benznidazole response in patients with chronic Chagas' disease: a prospective study in a non-disease-endemic country.
    Murcia L; Carrilero B; Muñoz MJ; Iborra MA; Segovia M
    J Antimicrob Chemother; 2010 Aug; 65(8):1759-64. PubMed ID: 20542903
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Chagas' disease: a search for treatment and a question--should the disease be of military concern?
    Kinnamon KE; Poon BT; Scovill JP; Hanson WL; Waits VB
    Mil Med; 1997 Aug; 162(8):527-32. PubMed ID: 9271903
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Trypanocidal treatment of Chagas disease.
    Pérez-Molina JA; Crespillo-Andújar C; Bosch-Nicolau P; Molina I
    Enferm Infecc Microbiol Clin (Engl Ed); 2021 Nov; 39(9):458-470. PubMed ID: 34736749
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Congenital Chagas' disease: diagnostic and clinical aspects.
    Freilij H; Altcheh J
    Clin Infect Dis; 1995 Sep; 21(3):551-5. PubMed ID: 8527542
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cell-mediated immunity in Chagas' disease: Alterations induced by treatment with a trypanocidal drug (nifurtimox).
    Lelchuk R; Cardoni RL; Fuks AS
    Clin Exp Immunol; 1977 Dec; 30(3):434-8. PubMed ID: 414867
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Estimating demand for anti-Chagas drugs: a contribution for access in Latin America].
    Chaves GC; Abi-Saab Arrieche M; Rode J; Mechali D; Reis PO; Alves RV; Stobbaerts E; Aguilar NG; Ribeiro I
    Rev Panam Salud Publica; 2017 Jun; 41():e45. PubMed ID: 28614468
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Is use of nifurtimox for the treatment of Chagas disease compatible with breast feeding? A population pharmacokinetics analysis.
    Garcia-Bournissen F; Altcheh J; Panchaud A; Ito S
    Arch Dis Child; 2010 Mar; 95(3):224-8. PubMed ID: 19948512
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Heart rate variability in chronic Chagas patients before and after treatment with benznidazole.
    Oliveira LF; Silva VJ; Lages-Silva E; Molina RJ; Fuzissaki J; Niederhaur S; Prata A; Correia D
    Auton Neurosci; 2010 Dec; 158(1-2):118-22. PubMed ID: 20558113
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Tolerance of benznidazole in a United States Chagas Disease clinic.
    Miller DA; Hernandez S; Rodriguez De Armas L; Eells SJ; Traina MM; Miller LG; Meymandi SK
    Clin Infect Dis; 2015 Apr; 60(8):1237-40. PubMed ID: 25601454
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Toxicity of nifurtimox as second-line treatment after benznidazole intolerance in patients with chronic Chagas disease: when available options fail.
    Crespillo-Andújar C; Chamorro-Tojeiro S; Norman F; Monge-Maillo B; López-Vélez R; Pérez-Molina JA
    Clin Microbiol Infect; 2018 Dec; 24(12):1344.e1-1344.e4. PubMed ID: 29906591
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effect of length of treatment with Bayer 2502 on isolation of Trypanosoma cruzi and resistance to challenge in the mouse.
    Morrow DT; Wescott RB; Davis WC
    Am J Trop Med Hyg; 1977 May; 26(3):382-6. PubMed ID: 405877
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Lack of sensitivity of sister-chromatid exchange for lymphocyte chromosomal damage detection caused by antichagasic treatment.
    Gorla NB; Ledesma OS; Barbieri GP; Larripa IB
    Toxicol Lett; 1991 Oct; 58(2):225-30. PubMed ID: 1949081
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Possibility of treatment in Chagas' disease].
    Prata A
    AMB Rev Assoc Med Bras; 1978 Apr; 24(4):140-2. PubMed ID: 98813
    [No Abstract]   [Full Text] [Related]  

  • 78. [Changes in parasitemia evaluated using the modified Strout method in patients with acute Chagas disease under treatment].
    Castro C; Emanuel A
    Rev Soc Bras Med Trop; 1988; 21(4):177-80. PubMed ID: 3152133
    [No Abstract]   [Full Text] [Related]  

  • 79. Effectiveness of Nifurtimox in the Treatment of Chagas Disease: a Long-Term Retrospective Cohort Study in Children and Adults.
    Falk N; Berenstein AJ; Moscatelli G; Moroni S; González N; Ballering G; Freilij H; Altcheh J
    Antimicrob Agents Chemother; 2022 May; 66(5):e0202121. PubMed ID: 35416710
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Contributions of toxicology to the problem of Chagas' disease (American Trypanosomiasis)--a year 2000 update.
    Castro JA
    Biomed Environ Sci; 2000 Dec; 13(4):271-9. PubMed ID: 11351860
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.